MISSION Therapeutics

What MISSION Therapeutics does

Mission Therapeutics is a privately held, clinical-stage biotechnology company founded in 2011 and headquartered at the Babraham Research Campus in Cambridge, United Kingdom. The company develops first-in-class small-molecule drugs that selectively inhibit deubiquitylating enzymes (DUBs), with its primary focus on USP30, a mitochondrial DUB whose inhibition enhances mitophagy — the cellular quality-control process that clears dysfunctional mitochondria. Its lead assets are MTX325, an orally bioavailable, brain-penetrant USP30 inhibitor in development for disease modification in Parkinson's Disease (currently progressing to a Phase Ib proof-of-mechanism trial in H1 2026), and MTX652, a peripherally-restricted USP30 inhibitor in Phase II for acute kidney injury following cardiac surgery. Mission's pipeline is built on a proprietary DUB platform spanning 55 explored targets that combines novel disease biology, bespoke screening tools and medicinal chemistry, with composition-of-matter IP on MTX325 extending through 2041 and academic collaborations anchored at the Universities of Cambridge, Oxford and Newcastle and at Harvard Medical School.

The company operates a capital-intensive, partnership-centric biotech business model. It has raised approximately £117 million (~$149 million) in total equity from a blue-chip institutional and corporate venture syndicate (Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group, Rosetta Capital), supplemented by roughly $5.7 million in grant funding from The Michael J. Fox Foundation and Parkinson's UK, and by milestone/royalty-linked economics from its 2018 collaboration with AbbVie covering DUB inhibitors for Alzheimer's and Parkinson's Disease (a $20 million milestone was triggered in 2021 on nomination of two DUB targets). Mission does not sell approved products; instead it advances programs through early clinical development with a patient-selection strategy intended to raise the probability of early efficacy readouts, and selectively partners selected programs with larger pharmaceutical companies for late-stage development and commercialisation. Its customer base is therefore counterparties rather than end payers, and its operating geographies for clinical trials already extend to North America and Europe for the MTX652 Phase II programme.

Name

MISSION Therapeutics

Legal name

Mission Therapeutics Ltd

Website

http://www.missiontherapeutics.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Clinical-stage biopharmaceuticals (small molecule DUB inhibitors)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Deubiquitylating enzyme inhibitors
• USP30 inhibitor drugs
• Mitophagy therapeutics
• Clinical stage biotechnology
• Small molecule drug discovery

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Partnership and Licensing: The company generates value by advancing pipeline programs through early clinical development and preferentially with a patient selection strategy to enhance probability of demonstrating early signs of efficacy. Selected programs may be advanced in partnership with other pharmaceutical companies. Under the AbbVie collaboration, Mission receives success-based milestones as well as royalty payments for each commercialized product.
2. Grant Funding: Mission Therapeutics receives grant funding from foundations such as The Michael J. Fox Foundation and Parkinson's UK to support clinical development of its drug candidates.
3. Equity Financing: The company raises venture capital from blue chip investors to fund its R&D operations and clinical development programs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

MISSION Therapeutics is a clinical-stage biotech that discovers and develops first-in-class small molecule drugs targeting disease-associated deubiquitylating enzymes (DUBs), principally USP30, to promote mitophagy and clear dysfunctional mitochondria. Its lead clinical assets are MTX325 (a CNS-penetrant USP30 inhibitor in Phase Ib for Parkinson's Disease) and MTX652 (a peripherally-restricted USP30 inhibitor in Phase II for acute kidney injury following cardiac surgery), supported by a proprietary DUB platform spanning 55 targets and partnerships such as the AbbVie collaboration for neurodegenerative DUB targets.

Product overview

Mission Therapeutics is a clinical-stage biotech developing first-in-class small molecule drugs that selectively target disease-associated deubiquitylating enzymes (DUBs), particularly USP30. The company's lead candidates are MTX325 (a CNS-penetrant USP30 inhibitor for Parkinson's disease, currently in Phase Ib) and MTX652 (a peripherally-restricted USP30 inhibitor for acute kidney injury, currently in Phase II). Both candidates work by inhibiting USP30 to promote mitophagy—the essential cellular process for removing dysfunctional mitochondria—thus improving overall cellular health and function.

Differentiator

Problem solved

Functional benefit

Products and services

• MTX325 First-in-class, highly potent and selective, orally bioavailable and brain-penetrant small-molecule USP30 inhibitor that promotes mitophagy to clear dysfunctional mitochondria and protect dopamine-producing neurons for disease modification in Parkinson's Disease. Currently in Phase Ib clinical development.
• MTX652 Potent and selective peripherally-restricted small-molecule USP30 inhibitor designed to improve mitochondrial quality and function by enhancing mitophagy for treatment of acute kidney injury associated with cardiac surgery. Currently in Phase II clinical development.

Quantifiable outcome

• Phase Ib proof-of-mechanism data in Parkinson's disease patients expected in H2 2027
• +3 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Five partnerships are on record, tiered core and minor.

• AbbViecoreStrategic or Co-development Partner · 1 November 2018Mission and AbbVie are collaborating to identify novel DUB targets and discover associated inhibitor compounds for neurodegenerative diseases including Alzheimer's and Parkinson's. AbbVie has the option to gain exclusive rights to develop and commercialize inhibitors of selected DUB targets and will pay Mission success-based milestones as well as royalty payments for each commercialized product. A $20 million milestone was received when AbbVie nominated two DUB targets to progress to the next stage of drug discovery.
• University of CambridgecoreStrategic or Co-development PartnerStrong collaborations with key academic and research centres including the Gurdon Institute Cancer Research UK Laboratories at the University of Cambridge. Collaborative research published in Nature Communications (2023) on USP30 and MTX325 in Parkinson's disease models.
• University of Oxford (Oxford Parkinson's Disease Centre)minorStrategic or Co-development PartnerCollaboration with leading UK centres in neurodegenerative diseases including the Oxford Parkinson's Disease Centre at the University of Oxford.
• Newcastle University (Wellcome Trust Mitochondrial Research Centre)minorStrategic or Co-development PartnerCollaboration with the Wellcome Trust Mitochondrial Research Centre at Newcastle University for mitochondrial research.
• Harvard Medical SchoolcoreStrategic or Co-development PartnerCollaborative research with Harvard Medical School scientists on USP30 and Parkinson's disease, with data presented at Society for Neuroscience conference and co-authorship on Nature Communications publication.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration and lysosomal storage diseases, including programs targeting mitophagy and mitochondrial dysfunction. Most directly comparable peer given shared focus on CNS/mitochondrial biology.
• Mitokinin: Private biotech developing small-molecule activators of the PINK1/Parkin pathway to enhance mitophagy for Parkinson's Disease. Closest mechanistic peer to Mission's USP30 mitophagy strategy.
• Stealth BioTherapeutics: Clinical-stage biotech developing mitochondria-targeted therapies for diseases involving mitochondrial dysfunction. Comparable as a direct peer in mitochondrial-targeted small-molecule drug development.
• Khondrion: European clinical-stage biotech developing small-molecule modulators of mitochondrial function for inherited mitochondrial diseases and primary mitochondrial disease. Direct peer in mitochondrial-targeted therapeutics.
• Prothena: Clinical-stage biotech developing protein-misfolding targeted therapies for neurodegenerative diseases including Parkinson's. Comparable peer in CNS drug development and disease-modifying approaches to PD.
• Prevail Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for Parkinson's Disease and other neurodegenerative disorders, now part of Eli Lilly. Comparable as a Parkinson's-focused clinical-stage peer.
• Caraway Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for lysosomal diseases and neurodegeneration, acquired by Eli Lilly. Comparable as a peer pursuing lysosomal/mitochondrial biology for CNS indications.

Broad incumbents

• Calico Life Sciences: Alphabet-backed life sciences company pursuing aging-related biology including neurodegeneration and mitochondrial dysfunction. Broad incumbent with overlapping scientific interests though significantly larger and more diversified.
• Astellas Pharma: Large Japanese pharmaceutical company with active programs in mitochondrial diseases and neurodegeneration, including collaborations and acquisitions in the space. Broad incumbent with overlapping therapeutic area focus.

Emerging players

• BioVie: Clinical-stage company developing NE3107, an investigational small molecule for Parkinson's Disease and other inflammatory-driven conditions. Comparable emerging peer in Parkinson's clinical development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/MISSIONTherapeu
• LinkedInlinkedin.com/company/mission-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds10 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MISSION Therapeutics